HR 124119th CongressIn Committee

Byron Nash Renal Medullary Carcinoma Awareness Act of 2023

Introduced: Jan 3, 2025

Standard Summary

Comprehensive overview in 1-2 paragraphs

This bill, titled the Byron Nash Renal Medullary Carcinoma Awareness Act of 2023, would amend the Medicaid portion of the Social Security Act to provide incentives for education about the risk of renal medullary carcinoma (RMC) to individuals with sickle cell disease who are covered by Medicaid. Specifically, it adds “renal medullary carcinoma” to a list of conditions for which educational incentives can be offered under Section 1903(a)(3)(E)(ii) of the Social Security Act. The change applies to items and services furnished on or after the enactment date. The bill was introduced in the House (H.R. 124) and referred to the Committee on Energy and Commerce; the sponsor is listed as Mr. Green of Texas. In short, the bill aims to ensure Medicaid recipients with sickle cell disease receive targeted education about the risk of RMC, by expanding the set of conditions for which incentivized education can be provided. The bill does not specify funding or program details beyond this addition, leaving implementation mechanics to future rulemaking or guidance.

Key Points

1Adds renal medullary carcinoma to the list of conditions (alongside stroke) for which Medicaid education incentives can be provided under Section 1903(a)(3)(E)(ii) of the Social Security Act.
2Target population: individuals with sickle cell disease who are recipients of Medicaid.
3Effective for items and services furnished on or after the enactment date.
4Named for Byron Nash; the act’s formal short title is in place but the bill’s status is “introduced” and referred to the Committee on Energy and Commerce.
5No explicit funding or detailed program design is included in the text; implementation details would be determined by implementing agencies (e.g., CMS) through regulations or guidance.

Impact Areas

Primary group/area affected- Medicaid beneficiaries with sickle cell disease, who would be the focus of the educational incentives regarding RMC risk.Secondary group/area affected- Healthcare providers and hospitals serving Medicaid/SCD patients, who may implement or participate in the educational programs.- Education and patient outreach organizations involved in RMC awareness.Additional impacts- Public health and early detection: Potential improvements in awareness about RMC risk could lead to more timely symptom recognition and referrals.- Budget and policy implementation: The bill does not specify funding levels or program mechanics, so CMS would need to establish how incentives are delivered, what forms of education are included, and how providers are compensated or encouraged to participate.- Monitoring and evaluation: If enacted, agencies might track uptake, educational reach, and any downstream effects on screening, diagnosis, or outcomes for RMC among SCD patients on Medicaid.

Generated by gpt-5-nano on Nov 18, 2025